Stockreport

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF PBCAR20A targets CD20 and is the Company’s second investigational allogeneic CAR T candidate advanced to the clinic FDA has authorized Precision to begin dosing with PB [Read more]